UTHRUnited Therapeutics Corporation

$24B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$799M+11.7% YoY

Gross Profit

$711M89.0% margin

Operating Income

$365M45.6% margin

Net Income

$310M38.8% margin

EPS (Diluted)

$6.41

QoQ Revenue Growth

+0.5%

Cash Flow

Operating Cash Flow

$192M

Free Cash Flow

$130M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$7.9B

Total Liabilities

$734M

Stockholders' Equity

$7.2B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$799M	$715M	+11.7%
Gross Profit	$711M	$637M	+11.6%
Operating Income	$365M	$320M	+13.9%
Net Income	$310M	$278M	+11.3%

Revenue Segments

Tyvaso

$470M59%

Remodulin

$135M17%

Orenitram

$124M16%

Unituxin

$58M7%

Adcirca

$7M1%

Product and Service, Other

$6M1%

Geographic Segments

UNITED STATES

$760M95%

Non-US

$39M5%

UTHR Q2 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena